Is statin-associated cognitive impairment clinically relevant? A narrative review and clinical recommendations;¿Es relevante clínicamente el daño cognitivo asociado a las estatinas? Un Repaso Narrativo y recomendaciones clínicas

Annals of Pharmacotherapy

Volumn 46, Issue 4, 2012, Pages 549-557

  Rojas Fernandez, Carlos H ^a,b   Cameron, Jean Christy F ^c  

^a UNIVERSITY OF WATERLOO   (Canada)

^b MCMASTER UNIVERSITY   (Canada)

^c MCMASTER UNIVERSITY   (Canada)

Author keywords

Clinical relevance; Cognitive impairment; Statins

Indexed keywords

ATORVASTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVINOLIN; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN;

ARTICLE; ATTENTION; CASE REPORT; CASE STUDY; COGNITION; COGNITIVE DEFECT; DEMENTIA; DISEASE ASSOCIATION; DRUG EFFECT; HUMAN; LIPOPHILICITY; MENTAL FUNCTION; OBSERVATIONAL STUDY; PRIORITY JOURNAL; PSYCHOMOTOR ACTIVITY; WORKING MEMORY;

BLOOD-BRAIN BARRIER; COGNITION; COGNITION DISORDERS; HUMANS; HYDROPHOBIC AND HYDROPHILIC INTERACTIONS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; TISSUE DISTRIBUTION;

EID: 84859704127     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1Q620     Document Type: Article

References (53)

1. Wang TJ, Stafford RS, Ausiello JC, Chaisson CE. Randomized clinical trials and recent patterns in the use of statins. Am Heart J 2001;141:957-63. DOI 10.1067/mhj.2001.115587
2. Genest J, McPherson R, Frohlich J, et al. 2009 Canadian Cardiovascular Society/Canadian guidelines for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease in the adult-2009 recommendations. Can J Cardiol 2009;25:567-79.
3. Armitage J. The safety of statins in clinical practice. Lancet 2007;370: 1781-90. DOI 10.1016/S0140-6736(07)60716-8
4. Peters JT, Garwood CL, Lepczyk M. Behavioral changes with paranoia in an elderly woman taking atorvastatin. Am J Geriatr Pharmacother 2008;6:28-32. DOI 10.1016/j.amjopharm.200
5. Galatti L, Polimeni G, Salvo F, Romani M, Sessa A, Spina E. Short-term memory loss associated with rosuvastatin. Pharmacotherapy 2006;26: 1190-2. DOI 10.1592/phco.26.8.1190
6. Padala KP, Padala PR, Potter JF. Simvastatin-induced decline in cognition. Ann Pharmacother 2006;40:1880-3. DOI 10.1345/aph.1H014
7. King DS, Wilburn AJ, Wofford MR, Harrell TK, Lindley BJ, Jones DW. Cognitive impairment associated with atorvastatin and simvastatin. Pharmacotherapy 2003;23:1663-7.
8. Orsi A, Sherman O, Woldeselassie Z. Simvastatin-associated memory loss. Pharmacotherapy 2001;21:767-9.
9. Wagstaff LR, Mitton MW, Arvik BML, Doraiswamy PM. Statin-associated memory loss: analysis of 60 case reports and review of the literature. Pharmacotherapy 2003;23:871-80.
10. Kurata T, Miyazaki K, Kozuki M, et al. Atorvastatin and pitavastatin improve cognitive function and reduce senile plaque and phosphorylated tau in aged APP mice. Brain Res 2011;1371:161-70. DOI 10.1016/j.brainres.2010.11.067
11. Wolozin B, Kellman W, Rousseau P, Celesia GG, Siegel G. Decreased prevalence of Alzheimer's disease associated with 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors. Arch Neurol 2000;57:1439-43.
12. Jick H, Zornberg GL, Jick SS, Seshadri S, Drachman DA. Statins and the risk of dementia. Lancet 2000;356:1627-31.
13. Rockwood K, Kirkland S, Hogan DB, et al. Use of lipid-lowering agents, indication bias, and the risk of dementia in community-dwelling elderly people. Arch Neurol 2002;59:223-7.
14. Neutel CI, Morrison H, Campbell NRC, de Groh M. Statin use in Canadians: trends, determinants and persistence. Can J Public Health 2007;98:412-6.
15. Estimated population of Canada, 1605 to present. CANSIM table 051-0001. Statistics Canada. 2009. www.statcan.gc.ca/pub/98-187-x/4151287-eng.htm (accessed 2011 Aug 7).
16. Harrison RW, Ashton CH. Do cholesterol-lowering agents affect brain activity? A comparison of simvastatin, pravastatin, and placebo in healthy volunteers. Br J Clin Pharmacol 1994;37:231-6.
17. Kostis JB, Rosen RC, Wilson AC. Central nervous system effects of HMG CoA reductase inhibitors: lovastatin and pravastatin on sleep and cognitive performance in patients with hypercholesterolemia. J Clin Pharmacol 1994;34:989-96.
18. Cutler N, Sramek J, Veroff A, Block G, Stauffer L, Lines C. Effects of treatment with simvastatin and pravastatin on cognitive function in patients with hypercholesterolaemia. Br J Clin Pharmacol 1995;39:333-6.
19. Santanello NC, Barber BL, Applegate WB, et al. Effect of pharmacologic lipid lowering on health-related quality of life in older persons: results from the cholesterol reduction in seniors program (CRISP) pilot study. J Am Geriatr Soc 1997;45:8-14.
20. Gibellato MG, Moore JL, Selby K, Bower EA. Effects of lovastatin and pravastatin on cognitive function in military aircrew. Aviat Space Environ Med 2001;72:805-12.
21. Golomb BA, Dimsdale JE, White HL, Criqui MH. Do low dose statins affect cognition? Results of the UCSD statin study. Circulation 2006;114:II-289.
22. Summers MJ, Oliver KR, Coombes JS, Fassett RG. Effect of atorvastatin on cognitive function in patients from the lipid lowering and onset of renal disease (LORD) trial. Pharmacotherapy 2007;27:183-90. DOI 10.1592/phco.27.2.183
23. Muldoon MF, Ryan CM, Sereika SM, Flory JD, Manuck SB. Randomized trial of the effects of simvastatin on cognitive functioning in hypercholesterolemic adults. Am J Med 2004;117:823-9. DOI 10.1016/j.amjmed.2004.07.041
24. Muldoon MF, Barger SD, Ryan CM, et al. Effects of lovastatin on cognitive function and psychological well-being. Am J Med 2000;108:538-47.
25. Gengo F, Cwudzinski D, Kinkel P, Block G, Stauffer L, Lines C. Effects of treatment with lovastatin and pravastatin on daytime cognitive performance. Clin Cardiol 1995;18:209-14.
26. Parale GP, Baheti NN, Kulkarni PM, Panchal NV. Effects of atorvastatin on higher functions. Eur J Clin Pharmacol 2006;62:259-65. DOI 10.1007/s00228-005-0073-z
27. Berk-Planken I, De Konig I, Stolk R, Jansen H, Hoogerbrugge N. Atorvastatin, diabetic dyslipidemia, and cognitive functioning. Diabetes Care 2002;25:1250-1.
28. Shepherd J, Blauw GJ, Murphy MB, et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet 2002;360:1623-30.
29. Trompet S, van Vliet P, de Craen AJM, et al. Pravastatin and cognitive function in the elderly. Results of the PROSPER study. J Neurol 2010;257:85-90. DOI 10.1007/s00415-009-5271-7
30. Collins R, Armitage J, Parish S, Sleight P, Peto R. Effects of cholesterollowering with simvastatin on stroke and other major vascular events in 20536 people with cerebrovascular disease or other high-risk conditions. Lancet 2004;363:757-67. DOI 10.1016/S0140-6736(04)15690-0
31. Hajjar I, Schumpert J, Hirth V, Wieland D, Eleazer GP. The impact of the use of statins on the prevalence of dementia and the progression of cognitive impairment. J Gerontol 2002;57A:M414-8.
32. Agostini JV, Tinetti MR, Han L, McAvay G, Foody JAM, Concato J. Effects of statin use on muscle strength, cognition, and depressive symptoms in older adults. J Am Geriatr Soc 2007;55:420-5. DOI 10.1111/j.1532-5415.2007.01071.x
33. Yaffe K, Barrett-Connor E, Lin F, Grady D. Serum lipoprotein levels, statin use, and cognitive function in older women. Arch Neurol 2002;59:378-84.
34. Starr JM, McGurn B, Whiteman M, Pattie A, Whalley LJ, Deary IJ. Life long changes in cognitive ability are associated with prescribed medications in old age. Int J Geriatr Psychiatry 2004;19:327-32. DOI 10.1002/gps.1093
35. Benito-León J, Louis ED, Vega S, Bermejo-Pareja F. Statins and cognitive functioning in the elderly: a population-based study. J Alzheimers Dis 2010;21:95-102. DOI 10.3233/JAD-2010-100180
36. Redelmeier DA, Thiruchelvam D, Daneman N. Delirium after elective surgery among elderly patients taking statins. CMAJ 2008;179:645-52.
37. Glasser SP, Wadley V, Judd S, et al. The association of statin use and statin type and cognitive performance: analysis of the reasons for geographic and racial differences in stroke (REGARDS) study. Clin Cardiol 2010;33:280-8. DOI 10.1002/clc.20758
38. Evans MA, Golomb BA. Statin-associated adverse cognitive effects: survey results from 171 patients. Pharmacotherapy 2009;29:800-11. DOI 10.1592/phco.29.7.800
39. Levine M, Walter S, Lee H, Haines T, Holbrook A, Moyer V. Users' guides to the medical literature. IV. How to use an article about harm. JAMA 1994;271:1615-9.
40. Isaacs LL. Evaluating anecdotes and case reports. Altern Ther Health Med 2007;13:36-8.
41. Golomb BA, Criqui MH, White H, Dimsdale JE. Conceptual foundations of the UCSD statin study. Arch Intern Med 2004;164:153-62. DOI 10.1001/archinte.164.2.153
42. Saher G, Simons M. Cholesterol and myelin biogenesis. Subcell Biochem 2010;51:489-508. DOI 10.1007/978-90-481-8622-8
43. Miron VE, Zehntner SP, Kuhlmann T, et al. Statin therapy inhibits remyelination in the central nervous system. Am J Pathol 2009;17:1880-90. DOI 10.2353/ajpath.2009.080947
44. Klopfleisch S, Merkler D, Schmitz M, et al. Negative impact of statins on oligodendrocytes and myelin formation in vitro and in vivo. J Neurosci 2008;28:13609-14. DOI 10.1523/JNEUROSCI.2765-08.2008
45. Langsjoen PH, Langsjoen AM. The clinical use of HMG CoA-reductase inhibitors and the associated depletion of coenzyme Q10. A review of animal and human publications. Biofactors 2003;18:101-11.
46. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383-9.
47. Baigent C, Keech A, Kearney PM, et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005;366:1267-78. DOI 10.1016/S0140-6736(05)67394-1
48. Di Paolo G, Kim TW. Linking lipids to Alzheimer's disease: cholesterol and beyond. Nat Rev Neurosci 2011;12:284-96. DOI 10.1038/nrn3012
49. Lefer AM, Scalia R, Lefer DJ. Vascular effects of HMG CoA-reductase inhibitors (statins) unrelated to cholesterol lowering: new concepts for cardiovascular disease. Cardiovasc Res 2001;49:281-7. DOI 10.1161/01.CIR.0000033635.42612.88
50. Muangpaisan W, Brayne C. Systematic review of statins for the prevention of vascular dementia or dementia. Geriatr Gerontol Int 2010;10:199-208. DOI 10.1111/j.1447-0594.2009.00579.x
51. Brass LM, Alberts MJ, Sparks L. An assessment of statin safety by neurologists. Am J Cardiol 2006;97:86C-8C. DOI 10.1016/j.amjcard.2005.12.017
52. McGowan MP. There is no evidence for an increase in acute coronary syndromes after short-term abrupt discontinuation of statins in stable cardiac patients. Circulation 2004;110:2333-5. DOI 10.1161/01.CIR.0000145118.55201.15
53. Schachter M. Chemical, pharmacokinetic and pharmacodynamic properties of statins: an update. Fundam Clin Pharmacol 2005;19:117-25. DOI 10.1111/j.1472-8206.2004.00299.x